SEC Form 4Coverage since Jul 20, 2026
$SGMT insider trading
Over the last 12 months, Sagimet Biosciences insiders reported no purchases and 3 sales totaling $719K across SEC Form 4 filings. 33% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $719K 3 events
- Events · 12m
- 3 Form 4 filings, grouped
- Insiders · 12m
- 3 distinct reporters
- 10b5-1 share
- 33% pre-arranged plans
Side
Price · $SGMT · 12Mvia TradingView
Top insiders · 12m
Rozek ElizabethChief Legal & Admin. Officer1× · $82K
Kemble George—1× · $141K
Happel DavidPresident & CEO1× · $497K
All insider trades
3 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 20, 2026 | Happel DavidPresident & CEO · O·D | ▼ Sale | 64,051 | $7.76 | $497K | -8% | — |
| Jul 20, 2026 | Rozek ElizabethChief Legal & Admin. Officer · O | ▼ Sale | 10,545 | $7.76 | $82K | -4.5% | — |
| Jul 20, 2026 | Kemble GeorgeD | ▼ Sale | 18,844 | $7.46 | $141K | -23.3% | plan |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $SGMT feed.